Highlights Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Market Closed - Nasdaq Other stock markets 01:30:00 29/06/2024 am IST			5-day change	1st Jan Change
84.26 ^USD	+2.34%		+6.13%	+17.98%

27/06	Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease	MT
18/06	Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Ligand Pharmaceuticals' Partner Gets US FDA Approval for Ohtuvayre to Treat Chronic Obstructive Pulmonary Disease	27/06	MT
Merck Receives FDA Approval for Capvaxive, Triggers $2 Million Payment for Ligand Pharmaceuticals	18/06	MT
Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE? (Pneumococcal 21-valent Conjugate Vaccine) for Adults	18/06	CI
Sector Update: Health Care Stocks Softer Late Afternoon	09/05	MT
Ligand Pharmaceuticals Shares Rise After Q1 Adjusted Earnings, Revenue Beat Views	08/05	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Posts Q1 Revenue $31M, vs. Street Est of $27.9M	08/05	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q1 EPS $1.20, vs. Street Est of $0.83	08/05	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Ligand Pharmaceuticals Incorporated Reaffirms Earnings Guidance for the Year 2024	08/05	CI
Sector Update: Health Care Stocks Stronger in Tuesday Afternoon Trading	07/05	MT
Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates	07/05	MT
Ligand Pharmaceuticals Incorporated Announces New Topiram Injection Data Presented At 9th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures Conference	08/04	CI
Ligand Pharmaceuticals Appoints Scott Plesha to the Role of Chief Executive Officer for Pelthos Therapeutics	03/04	CI
Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics	03/04	CI
Ligand Pharmaceuticals' Q4 Adjusted Earnings Rise, Revenue Falls; Reaffirms 2024 Guidance	27/02	MT
Ligand Pharmaceuticals Incorporated Re-Affirms Earnings Guidance for 2024	27/02	CI
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 Revenue $28.1M, vs. Street Est of $25.7M	27/02	MT
Earnings Flash (LGND) LIGAND PHARMACEUTICALS INCORPORATED Reports Q4 EPS $1.05, vs. Street Est of $0.66	27/02	MT
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	27/02	CI
Global markets live: Merck, Honda, Novartis, Boeing, Nvidia...	08/01

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Ligand Pharmaceuticals Incorporated

Equities

LGND

US53220K5048

Highlights

Filters